Abstract: A vinyl chloride resin composition comprising 100 parts by mass of a vinyl chloride resin and a co-ground mixture of (a) 0.001 to 10 parts by mass of at least one member selected from the group consisting of an organic phosphoric ester compound and a metal salt thereof and (b) 0.001 to 10 parts by mass of a grinding aid. The composition is excellent in transparency, heat stability, and heat discoloration resistance.

Abstract: The present invention relates to a reinforced thermoplastic resin composition comprising at least an amorphous thermoplastic resin (A), a flame retardant (B), fibrous calcium silicate (C) and an inorganic material (D) comprising talc and/or mica, the content of flame retardant (B) being 0.01 to 30 parts by weight based on 100 parts by weight of the amorphous thermoplastic resin (A); the content of fibrous calcium silicate (C) in said composition being 3 to 30% by weight, and the content of the inorganic material (D) comprising talc, mica or mixture thereof in said composition being 3 to 30% by weight.

Abstract: Disclosed are flame retardant compositions comprised of (a) brominated anionic styrenic polymer, and (b) at least one polybrominated alpha-omega diphenylalkane having a total of at least 6 bromine atoms directly bonded to the phenyl rings and in the range of 1 to 6 carbon atoms in the alkylene group disposed between the phenyl groups, and specified flame retarded polymer compositions with which have been blended (a) and (b) individually or in combination.

Abstract: The present invention relates to solutions and/or dispersions of organic semiconductors in a solvent mixture of at least two different organic solvents, characterized in that A. Each of the solvents on its own has a boiling point of below 200° C. and a melting point of 15° C. or less, B. at least one of the solvents has a boiling point in the range from greater than 140 to less than 200° C., C. the solvents used have no benzylic CH2 or CH groups, D. the solvents used are not benzene derivatives containing tert-butyl substituents or more than two methyl substituents, and their use in printing processes for producing layers of organic semiconductors, especially for the electronics industry.

Abstract: There is provided a run flat tire having a side reinforcing layer in which low exothermic property and high hardness are compatible and durability is improved. A rubber composition containing 10 to 100 parts by weight of carbon black with a nitrogen adsorption specific area of 30 to 100 m2/g and a dibutyl phthalate oil absorption amount of 50 ml/100 g or more and 2 parts by weight or more of sulfur or a sulfur compound, based on 100 parts by weight of a rubber component containing 10 to 50% by weight of a conjugated diolefin polymer or a copolymer of a diolefin and an aromatic vinyl compound having a primary amino group and an alkoxysilyl group and having a glass transition point of ?30° C. or less in which a bifunctional or more monomer is copolymerized in a polymer chain and/or at least a portion of a (co)polymer chain is coupled with a bifunctional or more coupling agent, and a run flat tire having a side reinforcing layer comprising the rubber composition.

Abstract: The present invention provides a material for slush molding which is improved in melt properties during slush molding and is excellent in heat resistance, the material being made up of a thermoplastic polyurethane resin (A) the difference between the softening starting temperature (STi) and the softening ending temperature by TMA being from 0 to 30° C., and STi being 135 to 200° C. The resin (A) has a hard segment with an Mn of 200 to 2000 comprising a diisocyanate having a symmetrical structure, a low molecular-weight diamine having a symmetrical structure, and/or a low molecular-weight diol, the content of which being from 5 to 50 wt %, and a soft segment making up of a high molecular-weight diol with an Mn of 500 to 5000, with the aromatic content being 35 wt % or less and the aromatic ring content x and the urea group content y satisfying ?0.1x+2.5?y??0.1x+6.

Abstract: [PROBLEMS] The invention is to provide an aqueous one-component coating agent that is environmentally friendly and safe, and is excellent in productivity and storage stability, and also in alkali resistance and solvent resistance of a coated film. [MEANS FOR SOLVING PROBLEMS] The problems are solved by providing a method for producing polyurethane emulsion for an aqueous one-component coating agent, comprising: reacting an organic diisocyanate (a1), a high molecular weight polyol (a2) and a low molecular weight glycol containing a carboxyl group (a3) to produce an isocyanate-terminated urethane prepolymer having a carboxyl group (A); mixing the urethane prepolymer (A) with a polyisocyanate containing a nonionic polar group (B); neutralizing the carboxyl group in the system with a neutralizing agent (C); and subjecting the mixture to emulsification in water and chain extension with water or an amine.

Abstract: A silylated polymer contains repeating units derived from butadiene. The polymer when partially silylated is especially useful for pressure sensitive adhesives where it imparts superior solvent resistance performance thereto.

Abstract: A method for controlling the flowability of polymer particles flowing downward in a densified form inside a polymerization reactor, in which one or more monomers are gas-phase polymerized in the presence of a polymerization catalyst, the density of solid (Kg of polymer per m3 of reactor occupied by the polymer) being higher than 80% of the “poured bulk density” of the polymer, the method being characterized in that a liquid stream is continuously fed into the polymerization reactor at a mass flow rate per unity of reactor surface higher than 30 Kg/h m2.

Abstract: The present invention relates to compounds of the formula (I): where M1 is an element of group 3, 4, 5 or 6 of the Periodic Table, X are halogen, hydrogen, C1-C20-alkyl, C2-C20-alkenyl, C6-C22-aryl, alkylaryl or arylalkyl, n is a natural number from 1 to 4. R1 is hydrogen or a C1-C40 radical, R2 is a substituted or unsubstituted C6-C40-aryl radical or C2-C40-heteroaromatic radical containing at least one heteroatom, R3 is hydrogen or a C1-C40 radical, or the radicals R2 and R3 together form a ring system, R4 is hydrogen or a C1-C40 radical, R5 is a C1-C40 radical, and Z is a divalent group CR8R9—CR10R11, where R8, R9, R10 and R11 are hydrogen or a C1-C40 radical.

Abstract: A process for preparing a functionalized polymerization initiator, the process comprising combining a functionalized styryl compound and an organolithium compound.

Abstract: A description is given of (meth)acrylic acid copolymers comprising methacrylic acid units and units based on isopropanol, the polymer being functionalized with aminoalkylsulfonic acid. In addition, a description is given of a process for the preparation thereof and the use thereof for watertreatment, scale inhibition in mineral oil extraction and corrosion inhibition in aqueous systems.

Abstract: It is an object of the present invention to provide a polycarboxylic acid polpolymer which improves the water reducing capacity and workability of cement compositions and the like and making them easier to handle when the fluidity and water reducing capacity are at the same levels, a method of producing the copolymer, and a cement additive and a cement composition comprising the copolymer. The present invention is further to provide a polycarboxylic acid copolymer and a cement additive which are capable of improving the strength and durability of hardening products of cement compositions, hence can advantageously be used in ultrahigh strength concrete. The present invention is polycarboxylic acid copolymers having high water reducing capacity, reducing the viscosity of cement compositions and improving the workability in applying cement.

Abstract: Disclosed is a method of preparing a catalyst for polymerization of aliphatic polycarbonates and a method of polymerizing an aliphatic polycarbonate. This method includes reacting a zinc precursor and organic dicarboxylic acid in a non-ionic surfactant-included solution.

Abstract: The invention provides a sterically hindered polymer that comprises a water-soluble and non-peptidic polymer backbone having at least one terminus covalently bonded to an alkanoic acid or alkanoic acid derivative, wherein the carbon adjacent to the carbonyl group of the acid or acid derivative group has an alkyl or aryl group pendent thereto. The steric effects of the alkyl or aryl group allow greater control of the hydrolytic stability of polymer derivatives. The polymer backbone may be poly(ethylene glycol).

Abstract: Disclosed is a method for purifying teicoplanin A2 comprising: (i) a primary pre-purification step of purifying a filtrate of fermentation broth of a strain using a synthetic adsorbent; (ii) a secondary pre-purification step of purifying the primary pre-purification solution using a cation exchange resin having a high cross-linkage, a catalytic resin or a chelate resin; (iii) a final purification step of purifying the secondary pre-purification solution using a reversed phase resin; and (iv) a powder-forming step. According to the present invention, it is possible to obtain teicoplanin A2 with a higher purity through a relatively simple process without using an excessive amount of an organic solvent.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.

Abstract: An alkaline protease having an amino acid with one or more amino acid residues selected from among those located at (a) position 63, (b) position 89, (c) position 120, (d) positions 63 and 187, (e) position 226, (f) position 296, (g) position 304 of the amino acid sequence of SEQ ID NO: 1, or at positions corresponding to these positions, are the following amino acid residues, respectively: (a): serine, (b): histidine, (c): arginine, (d): serine,(e): tyrosine, (f): valine, and (g): serine; and a gene encoding the alkaline protease.

Abstract: The invention provides isolated nucleic acids molecules, designated SLIC-1 nucleic acid molecules, which encode novel P-selectin glycoprotein ligand (PSGL-1) binding molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SLIC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a SLIC-1 gene has been introduced or disrupted. The invention still further provides isolated SLIC-1 proteins, fusion proteins, antigenic peptides and anti-SLIC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.

Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.

Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.

Abstract: The invention provides methods of using protein trans-splicing for the production of bispecific molecule which has a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds an antigenic molecule present in the circulatory system of a mammal. The invention also provides bispecific molecules produced by protein trans-splicing. The bispecific molecules of the invention can be used for the clearance of pathogenic antigenic molecules from the circulatory system of a mammal. The invention further provides methods of using protein trans-splicing for the production of polyclonal libraries of bispecific molecules, which comprise populations of bispecific molecules with different antigen recognition specificities. Such polyclonal libraries of bispecific molecules can be used for targeting multiple epitopes of a pathogenic antigenic molecule and/or multiple variants of a pathogenic antigenic molecule.

Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.

Abstract: An object of the present invention is to provide a chimera VEGF-E having a reduced antigenicity while maintaining the activity of VEGF-E. The present invention provides a chimera protein having an activity of growing vascular endothelial cells, which is obtained by substituting a part of the sequence of a VEGF analogous protein having an activity of vascularization that binds to KDR (VEGF receptor-2) but does not bind to Flt-1 (VEGF receptor-1) with a corresponding sequence of a human-derived VEGF analogous protein.

Abstract: Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type 1 diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type 1 diabetes patients.

Abstract: The invention relates to chromogenic compounds and the use thereof for the determination of enzymes of the family of carboxypeptidases N and carboxypeptidases U. The above is more specifically a compound of formula (I) in which A=(1), (2), (3), (4) or (5), R1, R2=H, —CH3, —CH(CH3)2, —OCH3, —Cl,—CF3,—OCF3,—SCH3, R3=an amino acid group which may be hydrolysed by a carboxypeptidase A and R4=a basic amino acid group.

Abstract: Labeled nucleotide analogs used in place of naturally occurring nucleoside triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reactions, and various analyses based thereon, including DNA sequencing, single base identification, hybridization assays and others.

Abstract: The methods of the invention provide a means for rapid analysis of gene function in a variety of systems. The invention allows screening of large libraries of nucleotide sequences for involvement in physiological pathways of interest. The methods of the invention also provide an efficient means of identifying and isolating nucleotide sequences that modulate a physiological pathway of interest from a population of nucleotide sequences.

Abstract: A screening method for identifying an individual having a pre-disposition towards having a cancer is disclosed, which screening method comprises the steps of: (a) obtaining a test sample comprising a nucleotide sequence comprised in a gene in a gene in a base excision repair (BER) pathway of the individual or an amino acid sequence of a polypeptide expressed thereby; and (b) comparing a region of the test sample sequence with the corresponding region of the wild type sequence, whereby a difference between the test sample sequence and the wild type sequence signifies that the individual is pre-disposed to having the cancer; and wherein the difference comprises a specified variation. The specified variation can be the known mutation in the human MYH protein, G382D-hMYH or a nucleotide sequence encoding it, or it can be one or more novel variations, namely, Y165C, E466X, and Y90X, or the respective corresponding nucleotide sequences.

Abstract: A synthetic, nuclear-encoded ND4 gene was linked to a mitochondrial targeting sequence and a FLAG epitope tag. This fusion construct was inserted into a rAAV vector. The ND4 fusion protein was expressed and imported into the mitochondria of cells harboring a mitochondrial DNA mutation (G11778A), where it restored cellular respiration.

Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.

Abstract: The present invention relates to a new polypeptide and the gene coding therefore, gene being an evolutionarily conserved actin-binding protein, called STARS (striated muscle activator of Rho signalin), that is expressed specifically in cardiac and skeletal muscle cells and is upregulated in response to calcineurin signaling during cardiac hypertrophy. STARS is localized to the thin filament of the sarcomere and to actin stress fibers where it promotes actin bundling. STARS stimulates the transcriptional activity of serum response factor (SRF) through a mechanism that requires actin bundling and Rho kinase activation. STARS provides a mechanism for selectively enhancing the transcriptional activity of SRF in muscle cells and for linking changes in actin dynamics to gene transcription. Also disclosed are methods of using the gene and protein in drug screening and therapy, including, for example, use of the gene in gene therapy to treat cardiovascular disease.

Abstract: The present invention provides isolated nucleic acids encoding delta DNA methyltransferase 3B molecules that are involved in the treatment and prevention of cancers such as, but not limited to, lung cancer. The delta DNA methyltransferase 3B molecules of the present invention are found to play a critical role in promoter-specific methylation of tumor suppressor genes. The DNA methyltransferase 3B molecules of the present invention are provided as therapeutic targets for identifying inhibitors of DNA methyltransferase. Such inhibitors are contemplated for the treatment and/or prevention of cancers. In particular embodiments, the present invention involves the treatment and prevention of a non-small cell lung cancer.

Abstract: The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterised in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the modified VLD is improved when compared with the unmodified VLD.

Abstract: The present invention provides a pancreatic islet transcription factor and methods of treating and diagnosing diabetes.

Abstract: A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.

Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

Abstract: This invention provides cellular gene products which have anti-apoptotic activity in HIV-1 infected cells and provides agents for the inhibition of the cellular gene products.

Abstract: Disclosed are a method for the reduction of an oligosaccharide mixture and an oligosaccharide mixture prepared thereby. In accordance with the disclosed invention, a mixture of oligosaccharides having a given DP profile is reduced to a DE of essentially zero by catalytically hydrogenating the mixture under reaction conditions sufficient to preserve the DP profile of the mixture, which reaction conditions typically include a reaction temperature ranging from about 50° C. to about 150° C. and a reaction pressure ranging up to about 1500 psi. Surprisingly, when the mixture is a malto-oligosaccharide mixture, the reduced mixture will have a superior color-fastness and thermal stability as compared to a similar unreduced mixture of malto-oligosaccharides, and also low reactivity towards nitrogen-containing species.

Abstract: Disclosed are salts of the general formula (I) wherein R1, R2 and B are defined in the description. These salts are useful intermediates for the preparation of cefdinir. Also, disclosed are processes for the preparation thereof from the compounds of the general formula (II) and (III). Further, disclosed is a method of producing cefdinir from the salts of the general formula (I) including the steps of removing protecting groups.

Abstract: Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.

Abstract: Compounds of formula wherein Rf is a (per)fluoropolyoxyalkylene chain having a number average molecular weight in the range 500-10,000; W1, W2, equal to or different from each other, are —F or —CF3; T1 is equal to —CHAa—Ba (CH2CH2O)na— wherein Aa=H, CF3; Ba=O, S, NH; na=0 or an integer between 1 and 6; T2 is equal to —F, —CF3, —C2 F5, —(C2 F4) Cl, or a group of formula: Q1, Q2 equal to or different from each other, are a chain of formula -T1-l -CFW1—O—Rf—CFW2-T?2, wherein: T?2 is equal to —F, —CF3, —C2 F5, —(C2F4) Cl; or is a group of formula: wherein B is equal to O, S, NH; R1, R2, R3, R4, R5 equal to or different from each other are selected from H, F, NO2, CN, C1-C8 perfluoroalkyl, carboxyl, phenyl (Ph), O- Ph, NH-Ph, S-Ph; wherein B is equal to O, S, NH; R1, R2, R3, R4, R5 equal to or different from each other are selected from H, F, NO2, CN, C1-C8 perfluoroalkyl, carboxyl, phenyl (Ph), O- Ph, NH-Ph, S-Ph; with the proviso that at least one of Q1 and Q2a is equal to:

Abstract: A process of preparing a compound of the formula (I) wherein B is chosen from OH, NH2, NHR, H or halogen; D is chosen from OH, NH2, NHR, H halogen or SCH3; R is an optionally substituted alkyl, aralkyl or aryl group; and Z is selected from OH, hydrogen, halogen, hydroxy, SQ or OQ, Q is an optionally substituted alkyl, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof, which comprises reacting a compound of the formula (II) with an anion produced by abstraction of the bromine or iodine atom from a compound of formula (XIX), to form a compound of formula (XX) The compound of formula (XX) is N- and O-deprotected to obtain the compound of formula (I).

Abstract: The formation of risperidone is enhanced by the use of enriched Z-isomer oxime intermediate(s) of formula (3) or (7). The oxime(s) can be isomerically enriched by a variety of techniques including the use of the novel acetic acid salt thereof, which affords, inter alia, resolution of the isomers and/or by heat conversion.

Abstract: The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.

Abstract: The present invention relates to a series of substituted indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Abstract: This invention relates to a method for N-demethylating an N-methyl morphinane comprising the steps of: (i) treating said N-methyl morphinane with an oxidizing agent to form the N-oxide morphinane; and (ii) treating said N-oxide morphinane with a reducing agent. This invention also relates to a method for oxidizing a ?7-morphinane compound to a ?6, ?8-morphinane compound, comprising the steps of treating said ?7-morphinane with ?-MnO2 for a time and under conditions sufficient to oxidize said ?7-morphinane, and treating the ?-MnO2 with glycol or a derivative thereof, and/or an inorganic salt.